A similar phenomena was described by Luo et al. [213] wherein co-treatment of enzalutamide and a CXCR7 inhibitor significantly decreased migration, VEGF secretion, and tumor growth in castration-resistant C4-2B and VCaP cells. The gene discussed is VEGFA; the disease is neoplasm.